广州中医药大学附属中山中医院药学部,广东 中山 528400
Received:31 August 2022,
Revised:2022-12-27,
Published:15 February 2023
移动端阅览
黄梨婷,王珠强,王依婷,等.蒙花苷体内外抗肺纤维化作用及其机制研究[J].中国药房,2023,34(03):333-338.
HUANG Liting,WANG Zhuqiang,WANG Yiting,et al.Study on the anti-pulmonary fibrosis effect of linarin in vivo and in vitro and its mechanism[J].ZHONGGUO YAOFANG,2023,34(03):333-338.
黄梨婷,王珠强,王依婷,等.蒙花苷体内外抗肺纤维化作用及其机制研究[J].中国药房,2023,34(03):333-338. DOI: 10.6039/j.issn.1001-0408.2023.03.15.
HUANG Liting,WANG Zhuqiang,WANG Yiting,et al.Study on the anti-pulmonary fibrosis effect of linarin in vivo and in vitro and its mechanism[J].ZHONGGUO YAOFANG,2023,34(03):333-338. DOI: 10.6039/j.issn.1001-0408.2023.03.15.
目的
2
考察蒙花苷的体内外抗纤维化作用,并初步探讨其作用机制。
方法
2
将C57BL/6J小鼠随机分为正常组(羧甲基纤维素钠)、模型组(羧甲基纤维素钠)、阳性对照组(吡非尼酮,200 mg/kg)和蒙花苷低、高剂量组(12.5、25 mg/kg),每组8只。除正常组外,其余各组小鼠均制备肺纤维化模型。造模结束后,灌胃给药,每天1次,连续14 d。观察小鼠一般情况,测定其肺指数,检测其血清中肿瘤坏死因子α(TNF-α)、转化生长因子β
1
(TGF-β
1
)水平以及肺组织中白细胞介素6(IL-6)水平;采用苏木素-伊红(HE)染色及Masson染色观察其肺组织病理学变化,并参照Ashcroft评分标准进行肺纤维化评分;检测其肺组织中
α
-平滑肌肌动蛋白(
α
-SMA)、Ⅰ型胶原蛋白(Collagen Ⅰ)、磷酸化胞外信号调节激酶(p-ERK1/2)、TGF-β
1
的表达水平。使用TGF-β
1
刺激人胚肺成纤维细胞HFL1建立体外肺纤维化模型,实验设置正常组、模型组和蒙花苷低、中、高浓度组(3.7、7.4、14.8 mg/L),培养48 h后,检测细胞中
α
-SMA、Collagen Ⅰ、p-ERK1/2蛋白表达水平。
结果
2
在体内实验中,与正常组比较,模型组小鼠肺指数和TNF-α、TGF-β
1
、IL-6水平均显著升高(
P
<0.01);肺泡中出现大量炎症浸染及细胞纤维化等病变,且有大量胶原蛋白沉积,HE染色和Masson染色评分均显著升高(
P
<0.01);肺组织中
α
-SMA、Collagen
Ⅰ、p-ERK1/2及TGF-β
1
蛋白表达均显著上调(
P
<0.01)。与模型组比较,蒙花苷高剂量组小鼠上述指标均显著改善(
P
<0.05或
P
<0.01),蒙花苷低剂量组大部分指标(除肺指数外)均显著改善(
P
<0.05或
P
<0.01)。在体外实验中,与空白组比较,模型组细胞出现密度变大、明显增殖等变化,细胞中
α
-SMA、Collagen Ⅰ和p-ERK1/2蛋白表达均显著上调(
P
<0.05或
P
<0.01)。与模型组比较,蒙花苷各浓度组细胞密度变小,形态逐渐恢复正常;蒙花苷高浓度组细胞中上述蛋白及蒙花苷中浓度组细胞中p-ERK1/2蛋白表达均显著下调(
P
<0.05或
P
<0.01)。
结论
2
蒙花苷可能通过调控ERK及炎症相关通路,减轻炎症反应,从而发挥抗肺纤维化作用。
OBJECTIVE
2
To investigate the anti-pulmonary fibrosis effect of linarin
in vivo
and
in vitro
, and investigate its mechanism preliminarily.
METHODS
2
C57BL/6J mice were randomly divided into normal group (carboxymethylcellulose sodium), model group (carboxymethylcellulose sodium), positive control group (pirfenidone, 200 mg/kg), linarin low-dose and high-dose groups (12.5, 25 mg/kg), with 8 mice in each group. Except for normal group, pulmonary fibrosis model was induced in other groups. After modeling, they were given relevant medicine intragastrically, once a day, for consecutive 14 d. The general situation of mice was observed, and their lung indexes were measured; the levels of tumor necrosis factor-α (TNF-α) and transforming growth factor-β
1
(TGF-β
1
) in serum and interleukin-6 (IL-6) in lung tissue were determined. Hematoxylin-eosin (HE) staining and Masson staining were used to observe the histopathological morphology of lung. The pulmonary fibrosis was scored according to Ashcroft score standard. The expressions of
α
-smooth muscle actin (
α
-SMA) and (type Ⅰ collagen, Collagen
Ⅰ), phosphorylated extracellular signal-regulated kinase (p-ERK1/2) and TGF-β
1
in lung tissues were detected. HFL1 cells were stimulated by TGF-β
1
to form pulmonary fibrosis model
in vitro
, which were divided into normal group, model group and linarin low-, medium- and high-concentration groups (3.7, 7.4, 14.8 mg/L). After being cultured for 48 h, the protein expressions of
α
-SMA, Collagen Ⅰ and p-ERK1/2 in HFL1 cells were detected.
RESULTS
2
In vivo
, compared with normal group, the lung index of model group and the levels of TNF-α, TGF-β
1
and IL-6 were significantly increased (
P
<0.01). There were a large number of inflammatory infiltration and cellular fibrosis lesions in the alveoli, and a large number of collagen depositions. The scores of HE staining and Masson staining were significantly increased (
P
<0.01). The protein expressions of
α
-SMA, Collagen
Ⅰ, p-ERK1/2 and TGF-β
1
in lung tissue were up-regulated significantly (
P
<0.01). Compared with model group, above indexes of mice were improved significantly in linarin high-dose group (
P
<0.05 or
P
<0.01), and most of indexes (except for lung index) were improved significantly in linarin low-dose group (
P
<0.05 or
P
<0.01).
In vitro
, compared with blank group, the density of cells in the model group increased, and obvious proliferation and other changes occurred; protein expressions of
α
-SMA, Collagen Ⅰ and p-ERK1/2 were significantly up-regulated (
P
<0.05 or
P
<0.01). Compared with model group, the cell density of each concentration group was decreased and the morphology gradually returned to normal; the expressions of above proteins in linarin high-concentrat
ion group and the protein expression of p-ERK1/2 in linarin medium-concentration group were down-regulated significantly(
P
<0.05 or
P
<0.01).
CONCLUSIONS
2
Linarin may regulate ERK and inflammatory pathways to reduce the inflammatory response, thereby exerting anti-pulmonary fibrosis effect.
NOBLE P W , BARKAUSKAS C E , JIANG D H . Pulmonary fibrosis:patterns and perpetrators [J ] . J Clin Invest , 2012 , 122 ( 8 ): 2756 - 2762 .
MAHER T M , BENDSTRUP E , DRON L , et al . Global incidence and prevalence of idiopathic pulmonary fibrosis [J ] . Respir Res , 2021 , 22 ( 1 ): 197 .
王彦君 , 王雪林 , 李欣泽 , 等 . 中医药治疗特发性肺纤维化研究 [J ] . 中国中医基础医学杂志 , 2021 , 27 ( 6 ): 1033 - 1035 .
LI L C , KAN L D . Traditional Chinese medicine for pulmonary fibrosis therapy:progress and future prospects [J ] . J Ethnopharmacol , 2017 , 198 : 45 - 63 .
GAO Y , LU J , ZHANG Y , et al . Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21 [J ] . Pulm Pharmacol Ther , 2013 , 26 ( 6 ): 649 - 654 .
JI Y , DOU Y N , ZHAO Q W , et al . Paeoniflorin suppresses TGF-β mediated epithelial-mesenchymal transition in pulmonary fibrosis through a Smad-dependent pathway [J ] . Acta Pharmacol Sin , 2016 , 37 ( 6 ): 794 - 804 .
CHEN C , YANG S M , ZHANG M , et al . Triptolide mitigates radiation-induced pulmonary fibrosis via inhibition of axis of alveolar macrophages-NOXes-ROS-myofibroblasts [J ] . Cancer Biol Ther , 2016 , 17 ( 4 ): 381 - 389 .
广东省药品监督管理局 . 广东省中药材标准:第三册 [S ] . 广州 : 广东科技出版社 , 2018 : 420 .
彭伟文 , 王英晶 . 黑面神的药用历史及现代研究概况 [J ] . 今日药学 , 2014 , 24 ( 8 ): 618 - 622 .
彭伟文 , 戴卫波 , 梅全喜 , 等 . 黑面神不同极性部位HPLC色谱与抗慢性皮炎-湿疹疗效的关联性研究 [J ] . 亚太传统医药 , 2016 , 12 ( 14 ): 41 - 45 .
MOTTAGHIPISHEH J , TAGHRIR H , BOVEIRI DEHSHEIKH A , et al . Linarin,a glycosylated flavonoid,with potential therapeutic attributes:a comprehensive review [J ] . Pharmaceuticals (Basel) , 2021 , 14 ( 11 ): 1104 .
ZHANG Y , LU W , ZHANG X , et al . Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways [J ] . Pharmacol Res , 2019 , 147 : 104307 .
NG B , DONG J R , D’AGOSTINO G , et al . Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis [J ] . Sci Transl Med , 2019 , 11 ( 511 ): eaaw1237 .
LIANG Q , CAI W Y , ZHAO Y X , et al . Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis [J ] . Pharmacol Res , 2020 , 158 : 104884 .
ASHCROFT T , SIMPSON J M , TIMBRELL V . Simple method of estimating severity of pulmonary fibrosis on a numerical scale [J ] . J Clin Pathol , 1988 , 41 ( 4 ): 467 - 470 .
WEI P , XIE Y , ABEL P W , et al . Transforming growth factor (TGF)-β 1 -induced miR-133a inhibits myofibroblast differentiation and pulmonary fibrosis [J ] . Cell Death Dis , 2019 , 10 ( 9 ): 670 .
TSUKUI T , SUN K H , WETTER J B , et al . Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis [J ] . Nat Commun , 2020 , 11 ( 1 ): 1920 .
LANCASTER L H , DE ANDRADE J A , ZIBRAK J D , et al . Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis [M ] . Eur Respir Rev , 2017 , 26 ( 146 ): 170057 .
ONG C H , THAM C L , HARITH H H , et al . TGF-β-induced fibrosis:a review on the underlying mechanism and potential therapeutic strategies [J ] . Eur J Pharmacol , 2021 , 911 : 174510 .
0
Views
526
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
